KRAS and pancreatic neoplasm: Statins was found to overcome resistance to PD-1 blockade therapies and improve the survival rate of KRAS mut tumor models of syngeneic colorectal cancer, genetically engineered lung and pancreatic tumors, indicating that KRAS mutation could be a molecular target for statins to elicit potent tumor-specific immunity (41).